BioPharm Insight 
BioPharm Insight is the premier online business intelligence tool used by most Business Development and Strategy teams- to help them more efficiently target, track and identify opportunitues and the competitive landscape. The best way to understand how you can leverage you personalized radar of real-time and proprietary intel, detailed deal comps, and forecasts, is to see an online demo of the tool. Please suggest the best time and place for us to show you exactly how we can help or visit us at www.biopharminsight.com
Mr Sam McDonald
Sr. Business Development ManagerBristol-Myers Squibb
Karen Martell
Transactions Lead - Biologics DiscoveryMr John Volpone
Regional Lead US/West Coast Search, Evaluation and DiligenceCadence Pharmaceuticals
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting with a current focus on already marketed or near to market hospital products.
Cadence has a highly experienced commercial group of 140+ hospital sales specialists, 14 MSLs and marketing team which are focused entirely on promotion to the hospital in the United States. Our sales force is currently promoting OFIRMEV™ (acetaminophen injection), which is indicated for the treatment of acute pain and fever and we are now looking to expand our product offering.
Mr Neil Berkley
Dir of BD
CalciMedica
CalciMedica is a clinical stage biotechnology company dedicated to the discovery and development of oral drugs to treat inflammatory and autoimmune diseases and organ transplant rejection. CalciMedica’s compounds are selective and potent inhibitors of the calcium release-activated calcium (CRAC) channels. The CRAC channel activates a signaling pathway that is essential for the adaptive immune response in T cells. The therapeutic value of inhibiting this pathway has been established by calcineurin inhibitors, a class of immunosuppressants that work downstream from the CRAC channel. Furthermore, the CRAC channel has been validated as a drug target in humans through the identification of a loss-of-function mutation. CalciMedica has discovered several potent and selective CRAC channel inhibitors (CCIs) that show anti-inflammatory activity in animal models. CalciMedica is developing its first clinical compound, CM2489, for the treatment of moderate-to-severe plaque psoriasis. CalciMedica recently completed a multiple-dose Phase 1 study with CM2489 in psoriasis patients and shown it to be safe, well-tolerated, and well-behaved with evidence of clinical improvement. CM2489 is the first CRAC channel inhibitor, or CCI, to be tested in humans. CalciMedica's pipeline of structurally diverse, potent and selective CRAC channel inhibitors has the potential to become a therapeutic platform, targeting multiple autoimmune indications.
Dr Gonul Velicelebi
CEOCampbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. The firm’s clients include all of the world’s top-20 pharmaceutical companies, hundreds of emerging and midsize biopharmaceutical companies, as well as a number of medical device and diagnostics companies. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Clinical Development, Commercial Effectiveness, Corporate Development, Medical Affairs, and Pricing and Market Access. From its locations in Cambridge, MA; Conshohocken, PA; Deerfield, IL; London, UK; Newtown, PA; New York, NY; Parsippany, NJ; Raleigh, NC; Somerset, NJ; South San Francisco, CA; Thousand Oaks, CA; and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan.
Mr Jeff Liepman
Regional General ManagerMr Tim Arendt
Executive Advisory GroupMr Jay Krippes
Executive Advisory BoardCapital Royalty, L.P.
Mr Luke Duster
PrincipalMr Nathan Hukill
Managing DirectorCivitas Therapeutics
Civitas is a privately-held pharmaceutical company focused on developing a robust pipeline of inhaled therapeutics with the clinically proven ARCUS(TM) dry powder platform. The company’s lead program for Parkinson’s disease, CVT-301, is intended to treat intermittent and debilitating motor fluctuations resulting from an inadequate response to patients’ standard oral medications. CVT-301 is currently enrolling a Phase 2 dose ranging study following the completion of a successful Phase 1 study which established clinical pharmacokinetic proof-of-concept at end of 2011. The product portfolio includes additional programs in respiratory disease, CNS disorders and infectious disease.
Mr Bryan Stuart
Chief Business Officer
Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc., a privately-held drug development company, is actively engaged in the development of first-in-class medicines to treat liver disease. Liver disease affects hundreds of million people worldwide and can be caused by many different injuries to the liver including Hepatitis C and other viral infections, obesity, alcohol or autoimmune diseases
Emricasan (IDN-6556) is a first-in-class oral small molecule compound to target apoptosis and treat liver fibrosis through a pan-caspase mechanism and is poised to enter Phase 3 registration studies in early 2013.
Emricasan is to be indicated for the treatment of HCV associated liver fibrosis in patients post orthotopic liver transplantation (POLT) to delay the progression of liver fibrosis to cirrhosis, and the treatment of acute liver failure in patients with underlying liver cirrhosis (ACLF) to improve transplant-free survival and decrease the incidence of progression to multi-organ failure. Both diseases are potentially orphan indications.
Emricasan has completed the initial regulatory carcinogenicity study in rasH2 mice with an outcome of no drug related tumors observed.
Conatus has a broad portfolio of 128 issued patents plus pending applications protecting compounds and six gene families related to apoptosis that comprise viable drug targets; with exclusivity of emricasan franchise to 2028 w/o extensions
Emricasan’s initial ACLF and POLT orphan indications combined represent a potential revenue opportunity of ~1.6 billion in peak sales in US and EU and the estimated market launch is: ACLF (Q3 2016), POLT (Q4 2017).
Conatus is seeking a global or regional partner to advance Emricisan to the market.
